BridgeBio Pharma annual return on equity
2018
2019
2020
BridgeBio Pharma Return on Equity (ROE) Growth & History (BBIO)
BridgeBio Pharma's return on equity was −216.78% for fiscal 2020.
View full BridgeBio Pharma company overviewBridgeBio Pharma annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2020 | 2020-12-31 | −216.78% | −136.99 pp |
| 2019 | 2019-12-31 | −79.79% | +4.78 pp |
| 2018 | 2018-12-31 | −84.57% | — |
BridgeBio Pharma quarterly return on equity
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q4 2020 | 2020-12-31 | −121.83% | −102.44 pp |
| Q3 2020 | 2020-09-30 | −60.61% | −41.13 pp |
| Q2 2020 | 2020-06-30 | −42.14% | −11.03 pp |
| Q1 2020 | 2020-03-31 | −26.38% | — |
| Q4 2019 | 2019-12-31 | −19.38% | — |
| Q3 2019 | 2019-09-30 | −19.48% | — |
| Q2 2019 | 2019-06-30 | −31.11% | — |
BridgeBio Pharma return on equity trends
Between the periods ended 2018-12-31 and 2020-12-31, BridgeBio Pharma's return on equity decreased from −84.57% to −216.78%, a change of −132.21 percentage points. The latest reported quarter, Q4 2020, shows −121.83%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BridgeBio Pharma source filings ↗